Merck’s Frazier Optimistic About Pipeline Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s Ken Frazier spoke about his faith in anaceptrapib, despite the recent failure of Tredaptive, at the recent Goldman Sachs Conference. He also addressed Merck’s pipeline and consolidation in the industry.